Publication at Faculty of Medicine in Pilsen |
2016
Abstract
Targeted chemotherapeutics and targeted biological therapy brought a significant shift in the treatment of NSCLC. These medicamnets achieve higher efficiency in comparison with conventional chemotherapy with minor adverse effects.
Moreover new molecules demonstrate possibility to overcome resistance caused by first generation drugs. The paper described molecules already in clinical use (that target sensitive EGFR mutation, ALK and ROS1 translocations and angiogensis inhibitors) as well as trends in the near future in this field.
New immunotherapeutic drugs are discussed in another article of this issue.